# DoD Kidney Cancer, Clinical Consortium Award

Source: https://welltoldgrants.com/grants/ht9425-23-kcrp-cca-dod-kidney-cancer-clinical-consortium-award/  
Official notice: https://www.grants.gov/search-results-detail/349278

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 7 awards worth $17.3 million in total. Applications closed on November 9, 2023.

| Field | Value |
|---|---|
| Opportunity number | HT9425-23-KCRP-CCA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | November 9, 2023 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 7 |
| Total funding | $17.3 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The Clinical Consortium Award mechanism provides support to develop and enhance collaborations and resources necessary for a network of organizations to rapidly execute phase 2 or phase 2-linked phase 1 (phase 1/2) kidney cancer clinical trials. These trials will include investigations of high-impact, novel therapeutic agents or approaches for the management or treatment of kidney cancer. Applicants are expected to demonstrate a broad understanding of kidney cancer research, including knowledge of the current state of clinical studies and priorities related to kidney cancer, and are encouraged to familiarize themselves with the FY23 KCRP’s Overarching Strategic Goals and Focus Areas and to consider this material when preparing their application. Support from this award is to be directed toward Consortium infrastructure needs rather than direct support of the trials themselves. The principal goal of the KCRP Clinical Consortium Award is to combine the efforts of leading investigators to bring to market high-impact, novel, therapeutic strategies and interventions to improve patient outcomes and significantly decrease the impact of the disease. To facilitate global investigations, U.S. and international institutions are encouraged to apply. Submissions from institutions with access to patients from high-risk, underserved, and/or military populations (as described in the FY23 KCRP Overarching Strategic Goals and Focus Areas) are especially encouraged. The FY23 Clinical Consortium Award mechanism will be used to select and fund six Clinical Research Sites and one Coordinating Center. PIs will be required to indicate whether the institution is applying as either the Coordinating Center with a Clinical Research Site or as a Clinical Research Site only. Institutions applying as the Coordinating Center, if not selected for funding, have the option to still be considered as a Clinical Research Site only. The Coordinating Center and Clinical Research Sites will be jointly responsible for proposing, selecting, and conducting phase 2 and phase 1/2 clinical trials focused on kidney cancer therapeutic interventions. The Coordinating Center and Clinical Research Sites funded by the FY23 KCRP Clinical Consortium Award will work with additional Clinical Research Sites that may be funded by the KCRP in future fiscal years. Additional details regarding the structure of the Consortium are described below.

## Questions people ask

### Is HT9425-23-KCRP-CCA still open?

No. It closed on November 9, 2023. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoD Kidney Cancer, Clinical Consortium Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoD Kidney Cancer, Clinical Consortium Award?

Closed November 9, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $17.3 million in total across about 7 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.